The Cost-Effectiveness of Rotavirus Vaccination in Armenia
This article, published in Vaccine, evaluates the cost-effectiveness of introducing infant rotavirus vaccination in Armenia in 2012 using Rotarix(R)® using a multiple birth cohort model. The model considered the cost and health implications of hospitalizations, primary health care consultations, and episodes not leading to medical care in children younger than five years old. Rotavirus vaccination is expected to cost the Armenian Ministry of Health US$220,000 in 2012, rising to $830,000 in 2016 following termination of co-financing from the GAVI Alliance, then declining to $260,000 in 2025 due to vaccine price maturity. Since the gross domestic product per capita of Armenia in 2008 was $3,800, rotavirus vaccination is likely to be regarded as “very cost-effective” from a World Health Organization standpoint. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Jit M, Yuzbashyan R, Sahakyan G, Avagyan T, Mosina L
» Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Jit M, Yuzbashyan R, Sahakyan G, Avagyan T, Mosina L. The Cost-Effectiveness of Rotavirus Vaccination in Armenia. Vaccine. 2011;29(48):9104-9111.
Resource types: Peer-reviewed journal
Regions: Eastern Europe